AYTU BIOPHARMA, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$122M
↑+5.0% +$6Mvs FY2024
Total Liabilities
$108M
↑+26.1% +$22Mvs FY2024
Equity
$14M
↓-53.8% -$17Mvs FY2024
Cash
$30M
↑+47.2% +$10Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $122M | $116M |
| Current Assets | $76M | $0 |
| Cash | $30M | $20M |
| ST Investments | $0 | $0 |
| Receivables | $31M | $25M |
| Inventory | $9M | $11M |
| Other Current | $7M | $0 |
| Non-Current Assets | $46M | $116M |
| PPE | $484K | $516K |
| Goodwill | $0 | $0 |
| Intangibles | $44M | $50M |
| Investments | $0 | $0 |
| Other Non-Current | $2M | $66M |
| Total Liab+Eq | $14M | $31M |
| Current Liab. | $66M | $64M |
| Accounts Payable | $14M | $12M |
| Short-Term Debt | $0 | $4M |
| Deferred Revenue | $0 | $0 |
| Other CL | $51M | $48M |
| Non-Current Liab. | $42M | $21M |
| Long-Term Debt | $10M | $10M |
| Other LT Liab. | $32M | $11M |
| Equity | $14M | $31M |
| Retained Earnings | $342M | $318M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · AYTU · Comparing FY2025 vs FY2024